Document is current
Any future updates will be listed below
-
Authors
Reimann, Adrian-Manuel
Schalk, Enrico
Jost, Felix
Mougiakakos, Dimitrios
Weber, Daniela
Döhner, Hartmut
Récher, Christian
Dumas, Pierre-Yves
Ditzhaus, Marc
Fischer, Thomas
Sager, Sebastian
-
Funding
Funding for this research was provided by:
FP7 Ideas: European Research Council (Consolidator Grant MODEST-647573)
Otto-von-Guericke-Universität Magdeburg
- License Information
-
More Information
Article History
Received: 8 June 2023
Accepted: 4 July 2023
First Online: 3 August 2023
Declarations
:
: DM consults for Abbvie, Beigene, BMS, Gilead, Janssen, Novartis, and Takeda. HD consults Abbvie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, Bristol Myers Squibb, Celgene, Daiichi Sankyo, GEMoaB, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Servier, Stemline, and Syndax. His institute has been receiving support from Abbvie, Agios, Amgen, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Kronos-Bio, Novartis, and Pfizer. CR is on the advisory boards of Abbvie, Astellas, BMS, Jazz Pharma, Novartis, Servier, and Takeda; his institution is supported by Abbvie, Astellas, BMS, Jazz Pharmaceuticals, and Iqvia. PYD consults for Daiichi-Sankyo, Jazz Pharmaceutical, Astellas, Abbvie, BMS, Janssen, and Novartis; his institution is supported by Astellas, Roche, Gilead, Daiichi-Sankyo, BMS, Servier, and Novartis. All other authors declare no competing interests.
